Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
Abstract
Recent reports estimate that 0.6% of adults in the United States, or approximately 1.4 million persons, identify as transgender. Despite gains in rights and media attention, the reality is that transgender persons experience health disparities, and a dearth of research and evidence-based guidelines remains regarding their specific health needs. The lack of research to characterize cardiovascular disease (CVD) and CVD risk factors in transgender populations receiving cross-sex hormone therapy (CSHT) limits appropriate primary and specialty care. As with hormone therapy in cisgender persons (that is, those whose sex assigned at birth aligns with their gender identity), existing research in transgender populations suggests that CVD risk factors are altered by CSHT. Currently, systemic hormone replacement for cisgender adults requires a nuanced discussion based on baseline risk factors and age of administration of exogenous hormones because of concern regarding an increased risk for myocardial infarction and stroke. For transgender adults, CSHT has been associated with the potential for worsening CVD risk factors (such as blood pressure elevation, insulin resistance, and lipid derangements), although these changes have not been associated with increases in morbidity or mortality in transgender men receiving CSHT. For transgender women, CSHT has known thromboembolic risk, and lower-dose transdermal estrogen formulations are preferred over high-dose oral formulations. In addition, many studies of transgender adults focus predominantly on younger persons, limiting the generalizability of CSHT in older transgender adults. The lack of randomized controlled trials comparing various routes and formulations of CSHT, as well as the paucity of prospective cohort studies, limits knowledge of any associations between CSHT and CVD.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Reisner SL, Poteat T, Keatley J, Cabral M, Mothopeng T, Dunham E, et al. Global health burden and needs of transgender populations: a review. Lancet. 2016;388:412-36. [PMID: 27323919] doi: 10.1016/S0140-6736(16)00684-X
2.
Flores A, Herman JL, Gates GJ, Brown TNT. How Many Adults Identify as Transgender in the United States? Los Angeles: The Williams Institute; 2016.
3.
Institute of Medicine. The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. Washington, DC: National Academies Pr; 2011. [PMID: 22013611]
4.
Schuster MA, Reisner SL, Onorato SE. Beyond bathrooms—meeting the health needs of transgender people. N Engl J Med. 2016;375:101-3. [PMID: 27376582] doi: 10.1056/NEJMp1605912
5.
Grant JM, Mottet LA, Tanis J, Harrison J, Herman JL, Keisling M. Injustice at Every Turn: A Report of the National Transgender Discrimination Survey. Washington, DC: National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011.
6.
Baker K, Highes M. Sexual orientation and gender identity data collection in the behavioral risk factor surveillance system. Center for American Progress. 2016. Accessed at www.americanprogress.org/issues/lgbt/report/2016/03/29/134182/sexual-orientation-and-gender-identity-data-collection-in-the-behavioral-risk-factor-surveillance-system on 8 January 2017.
7.
Gooren L, Lips P. Conjectures concerning cross-sex hormone treatment of aging transsexual persons. J Sex Med. 2014;11:2012-9. [PMID: 24775178] doi: 10.1111/jsm.12563
8.
Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 2013;10:3129-34. [PMID: 24010586] doi: 10.1111/jsm.12319
9.
Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935-59. [PMID: 24239921] doi: 10.1016/j.jacc.2013.11.005
10.
Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol. 2014;170:809-19. [PMID: 24616414] doi: 10.1530/EJE-14-0011
11.
Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev. 1987;8:1-28. [PMID: 3549275]
12.
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-31. [PMID: 11158037]
13.
Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab. 2015;100:1146-55. [PMID: 25548978] doi: 10.1210/jc.2014-3818
14.
Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007-19. [PMID: 21816776] doi: 10.1210/jc.2011-1137
15.
Culic V. Androgens in cardiac fibrosis and other cardiovascular mechanisms [Letter]. Int J Cardiol. 2015;179:190-2. [PMID: 25464442] doi: 10.1016/j.ijcard.2014.11.079
16.
Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc. 2013;2:e000272. [PMID: 24242682] doi: 10.1161/JAHA.113.000272
17.
Kloner RA, Carson C 3rd, Dobs A, Kopecky S, Mohler ER 3rd. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016;67:545-57. [PMID: 26846952] doi: 10.1016/j.jacc.2015.12.005
18.
Sumii K, Miyake H, Enatsu N, Matsushita K, Fujisawa M. Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy. Andrologia. 2016;48:198-202. [PMID: 25988884] doi: 10.1111/and.12433
19.
Hemnes AR, Maynard KB, Champion HC, Gleaves L, Penner N, West J, et al. Testosterone negatively regulates right ventricular load stress responses in mice. Pulm Circ. 2012;2:352-8. [PMID: 23130103] doi: 10.4103/2045-8932.101647
20.
Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108. [PMID: 23597181] doi: 10.1186/1741-7015-11-108
21.
Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050-8. [PMID: 22496507] doi: 10.1210/jc.2011-2591
22.
Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317:708-16. [PMID: 28241355] doi: 10.1001/jama.2016.21043
23.
Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-12. [PMID: 15082697]
24.
Bertone-Johnson ER, Manson JE. Early menopause and subsequent cardiovascular disease [Editorial]. Menopause. 2015;22:1-3. [PMID: 25490113] doi: 10.1097/GME.0000000000000385
25.
Rosano GM, Panina G. Cardiovascular pharmacology of hormone replacement therapy. Drugs Aging. 1999;15:219-34. [PMID: 10503814]
26.
Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-34. [PMID: 12904517]
27.
Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-84. [PMID: 12771114]
28.
LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305:1305-14. [PMID: 21467283] doi: 10.1001/jama.2011.382
29.
Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336:1227-31. [PMID: 18495631] doi: 10.1136/bmj.39555.441944.BE
30.
Wierckx K, Elaut E, Declercq E, Heylens G, DeCuypere G, Taes Y, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013;169:471-8. [PMID: 23904280] doi: 10.1530/EJE-13-0493
31.
Dhejne C, Öberg K, Arver S, Landén M. An analysis of all applications for sex reassignment surgery in Sweden, 1960-2010: prevalence, incidence, and regrets. Arch Sex Behav. 2014;43:1535-45. [PMID: 24872188] doi: 10.1007/s10508-014-0300-8
32.
Spieker LE, Noll G, Lüscher TF. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders. Am J Cardiovasc Drugs. 2001;1:293-303. [PMID: 14728028]
33.
Lüscher TF, Noll G. Endothelium dysfunction in the coronary circulation. J Cardiovasc Pharmacol. 1994;24 Suppl 3:S16-26. [PMID: 7700060]
34.
Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118:429-32. [PMID: 8439117]
35.
Giltay EJ, Toorians AW, Sarabdjitsingh AR, de Vries NA, Gooren LJ. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals. J Endocrinol. 2004;180:107-12. [PMID: 14709149]
36.
Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010;72:1-10. [PMID: 19473174] doi: 10.1111/j.1365-2265.2009.03632.x
37.
Chandra P, Basra SS, Chen TC, Tangpricha V. Alterations in lipids and adipocyte hormones in female-to-male transsexuals. Int J Endocrinol. 2010;2010. [PMID: 20706676] doi: 10.1155/2010/945053
38.
Emi Y, Adachi M, Sasaki A, Nakamura Y, Nakatsuka M. Increased arterial stiffness in female-to-male transsexuals treated with androgen. J Obstet Gynaecol Res. 2008;34:890-7. [PMID: 18834347] doi: 10.1111/j.1447-0756.2008.00857.x
39.
Bunck MC, Toorians AW, Lips P, Gooren LJ. The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals. Eur J Endocrinol. 2006;154:569-75. [PMID: 16556720]
40.
Marsche G. It's time to reassess the high-density lipoprotein (HDL) hypothesis: CSL112, a novel promising reconstituted HDL formulation [Editorial]. J Am Heart Assoc. 2015;4:e002371. [PMID: 26307571] doi: 10.1161/JAHA.115.002371
41.
Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res. 2010;51:2058-73. [PMID: 20371550] doi: 10.1194/jlr.R001610
42.
Asscheman H, Gooren LJ, Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism. 1989;38:869-73. [PMID: 2528051]
43.
Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164:635-42. [PMID: 21266549] doi: 10.1530/EJE-10-1038
44.
van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47:337-42. [PMID: 9373456]
45.
Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012;9:2641-51. [PMID: 22906135] doi: 10.1111/j.1743-6109.2012.02876.x
46.
Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause. 2011;18:1052-9. [PMID: 21775912] doi: 10.1097/gme.0b013e3182175e5c
47.
Shatzel JJ, Connelly KJ, DeLoughery TG. Thrombotic issues in transgender medicine: a review. Am J Hematol. 2017;92:204-8. [PMID: 27779767] doi: 10.1002/ajh.24593
48.
Ott J, Kaufmann U, Bentz EK, Huber JC, Tempfer CB. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93:1267-72. [PMID: 19200981] doi: 10.1016/j.fertnstert.2008.12.017
49.
Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab. 2003;88:5723-9. [PMID: 14671159]
50.
Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al; Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166:357-65. [PMID: 16476878]
51.
Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202-8. [PMID: 11988591]
52.
Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J. 2008;29:2031-41. [PMID: 18599555] doi: 10.1093/eurheartj/ehn299
53.
Gava G, Cerpolini S, Martelli V, Battista G, Seracchioli R, Meriggiola MC. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. Clin Endocrinol (Oxf). 2016;85:239-46. [PMID: 26932202] doi: 10.1111/cen.13050
54.
Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C, Carr S. Effects of high dose oestrogen therapy on circulating inflammatory markers. Maturitas. 2009;62:281-6. [PMID: 19231116] doi: 10.1016/j.maturitas.2009.01.009
55.
McCrohon JA, Walters WA, Robinson JT, McCredie RJ, Turner L, Adams MR, et al. Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol. 1997;29:1432-6. [PMID: 9180100]
56.
De Cuypere G, T'Sjoen G, Beerten R, Selvaggi G, De Sutter P, Hoebeke P, et al. Sexual and physical health after sex reassignment surgery. Arch Sex Behav. 2005;34:679-90. [PMID: 16362252]
57.
Meyer IH, Brown TN, Herman JL, Reisner SL, Bockting WO. Demographic characteristics and health status of transgender adults in select US regions: behavioral risk factor surveillance system, 2014. Am J Public Health. 2017;107:582-9. [PMID: 28207334] doi: 10.2105/AJPH.2016.303648
58.
Dhejne C, Lichtenstein P, Boman M, Johansson AL, Långström N, Landén M. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. PLoS One. 2011;6:e16885. [PMID: 21364939] doi: 10.1371/journal.pone.0016885
59.
Institute of Medicine Board on the Health of Select Populations. Collecting Sexual Orientation and Gender Identity Data in Electronic Health Records: Workshop Summary. Washington, DC: National Academies Pr; 2013. [PMID: 23967501]
60.
White Hughto JM, Reisner SL. A systematic review of the effects of hormone therapy on psychological functioning and quality of life in transgender individuals. Transgend Health. 2016;1:21-31. [PMID: 27595141]
61.
Rood BA, Reisner SL, Surace FI, Puckett JA, Maroney MR, Pantalone DW. Expecting rejection: understanding the minority stress experiences of transgender and gender-nonconforming individuals. Transgend Health. 2016;1:151-64.
62.
Meyer IH. Minority stress and mental health in gay men. J Health Soc Behav. 1995;36:38-56. [PMID: 7738327]
63.
Meyer IH. Does an improved social environment for sexual and gender minorities have implications for a new minority stress research agenda? Psychol Sex Rev. 2016;7:81-90. [PMID: 27642514]
64.
Mensah GA. Eliminating disparities in cardiovascular health: six strategic imperatives and a framework for action. Circulation. 2005;111:1332-6. [PMID: 15769777]
65.
Balsam KF, Molina Y, Beadnell B, Simoni J, Walters K. Measuring multiple minority stress: the LGBT People of Color Microaggressions Scale. Cultur Divers Ethnic Minor Psychol. 2011;17:163-74. [PMID: 21604840] doi: 10.1037/a0023244
66.
Hatzenbuehler ML, McLaughlin KA, Slopen N. Sexual orientation disparities in cardiovascular biomarkers among young adults. Am J Prev Med. 2013;44:612-21. [PMID: 23683979] doi: 10.1016/j.amepre.2013.01.027
67.
Deutsch MB. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. 2nd ed. San Francisco: Univ California; 2016.
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 167 • Number 4 • 15 August 2017
Pages: 256 - 267
History
Published online: 25 July 2017
Published in issue: 15 August 2017
Keywords
Copyright
© 2017 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann Intern Med.2017;167:256-267. [Epub 25 July 2017]. doi:10.7326/M17-0577
Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann Intern Med.2017;167:256-267. [Epub 25 July 2017]. doi:10.7326/M17-0577
View More
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to acponline.org to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Comments
0 Comments